SK Biopharma (326030.KS) Q1 2026: Cenobamate Lifts Operating Profit 250%, Margin Hits 39%
Single-drug operating leverage transforms SK Biopharmaceuticals from loss-making drug launcher to high-margin cash generator — operating margin more than doubles year-over-year.
Source: Q1 2026 Quarterly Report (16th Fiscal Year) — Filed May 15, 2026 with DART | Consolidated Financial Statements | Unit: ₩ billions
“SK Biopharma (326030.KS) Q1 2026: Cenobamate Lifts Operating Profit 250%, Margin Hits 39%”
This article became available on June 13, 2026. Subscribe to read in full, or wait until September 11, 2026 when it becomes free.
Cancel anytime. Full refund within 7 days.
You just read what happened. Here's how to read what it means.
LineVest Daily lands in your inbox before every opening bell: the key U.S. markets stories, earnings, disclosures and foreign flows — in plain English. Free, no card required.
We read SK Biopharma's latest SEC filing in full — financials under US GAAP, governance, and what it means for the stock. PDF in your inbox within 3 hours.
$12 · one-time
Get the SK Biopharma reportReading several U.S. stocks a week? Read every analysis article the moment it publishes — full daily U.S. market coverage plus the 90-day archive.
$9.99 · monthly
SubscribeIndependent journalism based on primary SEC filings — not investment advice. No brokerage affiliation.
